S&P 500   4,554.89
DOW   35,416.98
QQQ   390.19
Alibaba is down more than 10% since earnings, now what?
Secure your stake in the Smart Home industry. (Ad)
5 stocks for the Christmas wishlist: Hoping for a pullback
Teva Pharma is the way to play the re-rise of generic drugs
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Lemonade nears breakout, short interest surges, analysts bearish
ULTA stock is setting up to swing for the fences
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Get ready for Christmas shopping-sprees with these 2 winners
Li Auto smashes estimates proving EVs can be profitable
S&P 500   4,554.89
DOW   35,416.98
QQQ   390.19
Alibaba is down more than 10% since earnings, now what?
Secure your stake in the Smart Home industry. (Ad)
5 stocks for the Christmas wishlist: Hoping for a pullback
Teva Pharma is the way to play the re-rise of generic drugs
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Lemonade nears breakout, short interest surges, analysts bearish
ULTA stock is setting up to swing for the fences
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Get ready for Christmas shopping-sprees with these 2 winners
Li Auto smashes estimates proving EVs can be profitable
S&P 500   4,554.89
DOW   35,416.98
QQQ   390.19
Alibaba is down more than 10% since earnings, now what?
Secure your stake in the Smart Home industry. (Ad)
5 stocks for the Christmas wishlist: Hoping for a pullback
Teva Pharma is the way to play the re-rise of generic drugs
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Lemonade nears breakout, short interest surges, analysts bearish
ULTA stock is setting up to swing for the fences
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Get ready for Christmas shopping-sprees with these 2 winners
Li Auto smashes estimates proving EVs can be profitable
S&P 500   4,554.89
DOW   35,416.98
QQQ   390.19
Alibaba is down more than 10% since earnings, now what?
Secure your stake in the Smart Home industry. (Ad)
5 stocks for the Christmas wishlist: Hoping for a pullback
Teva Pharma is the way to play the re-rise of generic drugs
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Lemonade nears breakout, short interest surges, analysts bearish
ULTA stock is setting up to swing for the fences
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Get ready for Christmas shopping-sprees with these 2 winners
Li Auto smashes estimates proving EVs can be profitable

IRIDEX Stock Price, News & Analysis (NASDAQ:IRIX)

$2.57
+0.19 (+7.98%)
(As of 11/28/2023 ET)
Compare
Today's Range
$2.30
$2.59
50-Day Range
$1.90
$3.28
52-Week Range
$1.31
$3.48
Volume
77,698 shs
Average Volume
50,444 shs
Market Capitalization
$41.76 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.00

IRIDEX MarketRank™ Stock Analysis

Analyst Rating
0.00 Rating Score
Upside/​Downside
22.2% Downside
$2.00 Price Target
Short Interest
Healthy
2.64% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.85mentions of IRIDEX in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.50) to ($0.42) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

0.83 out of 5 stars

Computer And Technology Sector

592nd out of 597 stocks

Electromedical Equipment Industry

22nd out of 22 stocks


IRIX stock logo

About IRIDEX Stock (NASDAQ:IRIX)

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.

IRIX Stock Price History

IRIX Stock News Headlines

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Iridex: Q3 Earnings Insights
IRIDEX Corp IRIX
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Dow Gains Over 100 Points; Fed Leaves Interest Rates Unchanged
BYU, WE and IRIX among pre-market losers
Iridex Reports Second Quarter 2023 Financial Results
IRIDEX earnings preview: what Wall Street is expecting
Iridex: Q1 Earnings Insights
See More Headlines
Receive IRIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IRIDEX and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/11/2021
Today
11/28/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/14/2024

Industry, Sector and Symbol

Industry
Electromedical equipment
Sub-Industry
N/A
Current Symbol
NASDAQ:IRIX
Employees
130
Year Founded
1989

Price Target and Rating

Average Stock Price Target
$2.00
High Stock Price Target
$2.00
Low Stock Price Target
$2.00
Potential Upside/Downside
-22.2%
Consensus Rating
Rating Score (0-4)
0.00
Research Coverage
0 Analysts

Profitability

Net Income
$-7,550,000.00
Pretax Margin
-14.13%

Debt

Sales & Book Value

Annual Sales
$56.97 million
Book Value
$1.08 per share

Miscellaneous

Free Float
15,241,000
Market Cap
$41.76 million
Optionable
Not Optionable
Beta
0.88

Social Links

10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report














IRIX Stock Analysis - Frequently Asked Questions

What is IRIDEX's stock price target for 2024?

0 analysts have issued 12-month target prices for IRIDEX's stock. Their IRIX share price targets range from $2.00 to $2.00. On average, they expect the company's share price to reach $2.00 in the next year. This suggests that the stock has a possible downside of 22.2%.
View analysts price targets for IRIX
or view top-rated stocks among Wall Street analysts.

How have IRIX shares performed in 2023?

IRIDEX's stock was trading at $2.01 at the beginning of the year. Since then, IRIX shares have increased by 27.9% and is now trading at $2.57.
View the best growth stocks for 2023 here
.

Are investors shorting IRIDEX?

IRIDEX saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 319,200 shares, an increase of 79.9% from the October 31st total of 177,400 shares. Based on an average trading volume of 129,600 shares, the days-to-cover ratio is presently 2.5 days. Approximately 2.6% of the company's shares are sold short.
View IRIDEX's Short Interest
.

When is IRIDEX's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 14th 2024.
View our IRIX earnings forecast
.

How were IRIDEX's earnings last quarter?

IRIDEX Co. (NASDAQ:IRIX) announced its earnings results on Thursday, November, 11th. The medical equipment provider reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.01. The medical equipment provider had revenue of $13.26 million for the quarter, compared to the consensus estimate of $11.90 million. IRIDEX had a negative trailing twelve-month return on equity of 49.98% and a negative net margin of 14.21%. During the same quarter in the prior year, the company posted ($0.12) EPS.

What is Theodore A. Boutacoff's approval rating as IRIDEX's CEO?

7 employees have rated IRIDEX Chief Executive Officer Theodore A. Boutacoff on Glassdoor.com. Theodore A. Boutacoff has an approval rating of 64% among the company's employees.

What other stocks do shareholders of IRIDEX own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IRIDEX investors own include NVIDIA (NVDA), Trevena (TRVN), CTI BioPharma (CTIC), Agile Therapeutics (AGRX), Genocea Biosciences (GNCA), Idera Pharmaceuticals (IDRA), Lipocine (LPCN), Rigel Pharmaceuticals (RIGL) and SCYNEXIS (SCYX).

Who are IRIDEX's major shareholders?

IRIDEX's stock is owned by many different institutional and retail investors. Top institutional investors include AMH Equity Ltd (3.93%), Perkins Capital Management Inc. (0.25%), Acadian Asset Management LLC (0.18%), Wolverine Trading LLC (0.00%), FNY Investment Advisers LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Nandini Devi and Robert Earle Grove.
View institutional ownership trends
.

How do I buy shares of IRIDEX?

Shares of IRIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:IRIX) was last updated on 11/29/2023 by MarketBeat.com Staff

My Account -